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Abstract Although osteoporosis is a
systemic disease, vertebral fractures
due to spinal bone loss are a fre-
quent, sometimes early and often ne-
glected complication of the disease,
generally associated with consider-
able disability and pain. As osteo-
porotic vertebral fractures are an im-
portant predictor of future fracture
risk, including at the hip, medical
management is targeted at reducing
fracture risk. A literature search for
randomized, double-blind, prospec-
tive, controlled clinical studies ad-
dressing medical treatment possibili-
ties of vertebral fractures in post-
menopausal Caucasian women was
performed on the leading medical
databases. For each publication, the
number of patients with at least one
new vertebral fracture and the num-
ber of randomized patients by treat-
ment arm was retrieved. The relative
risk (RR) and the number needed to
treat (NNT, i.e. the number of pa-
tients to be treated to avoid one ra-
diological vertebral fracture over the
duration of the study), together with
the respective 95% confidence inter-
vals (95%CI) were calculated for
each study. Treatment of steroid-in-
duced osteoporosis and treatment of
osteoporosis in men were reviewed
separately, based on the low number
of publications available. Forty-five
publications matched with the search
criteria, allowing for analysis of 
15 different substances tested regard-
ing their anti-fracture efficacy at the
vertebral level. Bisphosphonates,
mainly alendronate and risedronate,
were reported to have consistently
reduced the risk of a vertebral frac-
ture over up to 50 months of treat-
ment in four (alendronate) and two
(risedronate) publications. Raloxi-
fene reduced vertebral fracture risk
in one study over 36 months, which
was confirmed by 48 months’ fol-
low-up data. Parathormone (PTH)
showed a drastic reduction in verte-
bral fracture risk in early studies,
while calcitonin may also be a treat-
ment option to reduce fracture risk.
For other substances published data
are conflicting (calcitriol, fluoride)
or insufficient to conclude about effi-
cacy (calcium, clodronate, etidronate,
hormone replacement therapy,
pamidronate, strontium, tiludronate,
vitamin D). The low NNTs for the
leading substances (ranges: 15–64
for alendronate, 8–26 for risedronate,
23 for calcitonin and 28–31 for ral-
oxifene) confirm that effective and
efficient drug interventions for treat-
ment and prevention of osteoporotic
vertebral fractures are available. Bis-
phosphonates have demonstrated
similar efficacy in treatment and pre-
vention of steroid-induced and male
osteoporosis as in postmenopausal
osteoporosis. The selection of the ap-
propriate drug for treatment of verte-
bral osteoporosis from among a bis-
phosphonate (alendronate or rise-
dronate), PTH, calcitonin or raloxi-
fene will mainly depend on the effi-
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Introduction
Osteoporosis was defined at a 1993 consensus conference
as “a systemic skeletal disease characterized by low bone
mass and micro-architectural deterioration of bone tissue
with a resultant increase in fragility and risk of fracture”
[24]. As bone quality cannot be evaluated easily in daily
practice, the diagnosis of osteoporosis is made on low
bone mineral density (BMD), expressed as the number of
standard deviations above or below BMD for normal
young adults (T-score). The World Health Organization
study group’s definition of osteoporosis is a T-score below
–2.5 SD. Patients with a T-score below –2.5 who also
have suffered a fragility fracture have severe osteoporosis
[91].
Although a number of risk factors for osteoporotic
fractures have been identified [26, 35], a history of previ-
ous vertebral fracture is a particularly important risk fac-
tor for future fractures. Postmenopausal women with radi-
ographically detected vertebral fractures are at increased
risk for new fractures, independently of bone mass [9, 17,
79]. In addition, vertebral fractures are common: 5% of
Caucasian women aged 50 and 25% of those aged 80 have
one or more fractures [58], and as many as 11–56% of pa-
tients on long-term steroids are estimated to have preva-
lent vertebral fragility fractures [3, 52, 60]. Vertebral frac-
tures, even those not recognized clinically, are associated
with substantial increases in back pain, functional limita-
tion, disability, and with an excess mortality risk [44, 63].
However, physicians frequently do not diagnose osteo-
porosis in primary care patients with vertebral fractures,
thereby missing an important preventive opportunity for
patients at highest risk for future fractures: in a recently
published study from Neuner et al., only 38% of subjects
with vertebral compression fractures noted on routine ra-
diographs (46% of women and 19% of men) were diag-
nosed with osteoporosis, and only 32% received prescrip-
tion medication for osteoporosis [62].
Effective medical treatments of osteoporosis have in-
creasingly become available over the last decade and their
efficacy in reducing fracture risk, including at the spine,
has been reviewed thoroughly in several recent publica-
tions [39, 45, 65].
The aim of this publication is to review the available
data on drug treatment options in women with postmeno-
pausal osteoporosis, with special focus on vertebral frac-
ture risk reduction, and to briefly comment on steroid-in-
duced osteoporosis and osteoporosis in men.
Materials and methods
We searched Medline, Embase and Current Contents from 1980 to
2002 for randomized controlled trials with drug treatment inter-
vention in Caucasian women with postmenopausal osteoporosis
(defined as T-score below –2SD at inclusion and/or prevalent
anamnestic fracture) and reporting vertebral fracture data (either as
a primary or secondary endpoint or as an adverse event). Dupli-
cates, abstracts, and posters were eliminated by manual selection.
All definitions of radiological vertebral fractures (anterior, mid-
dle, or posterior vertebral height loss defined as any % loss and/or
as any absolute value in millimeters), as chosen by the authors,
were accepted for inclusion in the final analysis. Published results
on risk reduction of clinically symptomatic vertebral fractures and
risk reduction of multiple fractures were recorded separately.
Studies reporting on the number of patients who suffered at
least one fracture were retained. Studies reporting on total number
of fractures (i.e., fracture rates in patient-years) per treatment
group without mentioning the number of patients with fractures
were excluded from the analysis. Counting events instead of pa-
tients has been criticized as violating basic statistical assumptions
and invalidating the use of common statistical tests as well as cross
comparisons [93].
Studies of less than 36 months’ duration were eliminated. The
minimum required duration for a phase III trial for development of
anti-osteoporotic drugs is usually specified at 3 years in Europe
and in the US, the European CPMP regulations being the most
stringent, requiring demonstrated anti-fracture efficacy prior to
registration of an osteoporosis drug [14].
For each publication, the number of patients with a at least one
new vertebral fracture and the number of randomized patients by
treatment arm was recorded. The relative risk (RR) and the number
needed to treat (NNT, i.e. the number of patients to be treated to
avoid one radiological vertebral fracture over the duration of the
study) as well as the respective 95% confidence intervals were cal-
culated. When different dosages were used in different treatment
arms, the results were pooled (active vs control) and dosage-spe-
cific comments as stated in the original publication were reported
if appropriate.
For steroid-induced osteoporosis and osteoporosis in men, an
overview is given based on selected publications.
Results
Forty-five publications resulted from the search of the
medical databases. Six publications were excluded be-
cause they reported on total number of fractures and the
number of patients with at least one fracture was not pub-
lished and could not be derived from published data [34,
46, 73, 76, 80, 85]. Sixteen publications were excluded
because the duration of observation was less than 36
months [5, 7, 15, 21, 29, 32, 33, 36, 41, 53, 55, 59, 66, 67,
90, 92]. Twenty-three publications matched all selection
criteria: four with alendronate [10, 11, 27, 50], two with
calcitriol [31, 86], one with calcium-vitamin D [69], one
cacy, tolerability and safety profile,
together with the patient’s willing-
ness to comply with a long-term
treatment. Although reduction of
vertebral fracture risk is an important
criterion for decision making, drugs
with proven additional fracture risk
reduction at all clinically relevant
sites (especially at the hip) should be
the preferred options.
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with calcitonin [20], two with etidronate [37, 54], three
with fluoride [68, 71, 77], one with hormone replacement
therapy [70], one with ipriflavone [6], one with pamidronate
[16], two with parathormone [51, 61], two with raloxifene
[28, 30] and three with risedronate [22, 38, 72]. The study
of Neer et al. with parathormone [61] had a median dura-
tion of only 21 months, but was kept in the final analysis
as it was stopped early by the sponsor.
Radiological vertebral fractures
An overview of all calculated RR and NNT values with
the respective 95% confidence interval (CI) by drug and
by study is given in Table 1. Figure 1 shows the RR and
95%CI for selected drugs in alphabetical order (alen-
dronate, calcitonin, parathormone (teriparatide, PTH),
raloxifene and risedronate).
Alendronate
In three long-term endpoint trials [10, 27, 50] and in one
published re-analysis of the anti-fracture efficacy in pa-
tients with osteoporosis as defined by the WHO [11], 
alendronate showed a consistent and significant reduction
in vertebral fracture risk of between 45 and 49% across all
studies. The calculated NNT ranged from 15 (95%CI 10
to 24) to 64 (95%CI 38 to 152), depending on the patient
population studied, patients with highest fracture risk hav-
ing the lowest NNTs.
Calcitonin
Only one published clinical trial of more than 36 months’
duration was retrieved [20]. Although the vertebral frac-
ture risk is reported to be significantly reduced, by 33%,
at the intranasal dose of 200 IU per day in the original
publication, the risk reduction of the pooled dosages (100,
Mths Total no. NPFx/NPR NPFx/NPR RR (95%CI) NNT (95%CI)
of subjects Active Controls
Radiological vertebral fractures
Alendronate [27] 50 4432 43/2214 78/2218 0.55 (0.38 to 0.79) 64 (38 to 152)
Alendronate [11] 48 3658 107/1841 197/1817 0.54 (0.43 to 0.67) 20 (14 to 31)
Alendronate [10] 36 2027 78/1022 145/1005 0.53 (0.41 to 0.68) 15 (10 to 24)
Alendronate [50] 36 994 17/597 22/397 0.51 (0.28 to 0.95) 38 (18 to 349)
Calcitonin [20] 60 1255 171/944 70/311 0.81 (0.63 to 1.03) 23 (10 to –154)
Calcitriol [86] 36 622 66/314 155/308 0.42 (0.33 to 0.52) 4 (2 to 5)
Calcitriol [31] 36 86 10/47 6/39 1.38 (0.55 to 3.45) –15 (12 to –3)
Calcium VitD [69] 52 191 27/91 34/100 0.87 (0.58 to 1.33) 24 (5 to –11)
Etidronate [37] 36 380 28/196 51/184 0.55 (0.36 to 0.82) 8 (4 to 18)
Etidronate [54] 48 100 4/50 9/50 0.44 (0.15 to 1.3) 11 (3 to –95)
Fluoride [71] 48 164 2/84 8/80 0.25 (0.6 to 1.01) 14 (6 to 67)
Fluoride [77] 36 144 20/99 30/45 0.3 (0.2 to 0.47) 3 (1 to 4)
Fluoride [68] 48 110 7/54 22/56 0.33 (0.16 to 0.66) 4 (2 to 8)
HRT [70] 42 128 3/64 4/64 0.75 (0.18 to 3.22) 65 (9 to –20)
Ipriflavone [6] 36 472 7/233 8/239 0.9 (0.33 to 2.44) 292 (25 to –40)
Pamidronate [16] 36 91 5/46 15/45 0.33 (0.14 to 0.78) 5 (2 to 13)
PTH [61] 21 1637 41/1093 64/544 0.32 (0.22 to 0.46) 13 (9 to 20)
PTH [51] 36 34 1/17 4/17 0.25 (0.04 to 1.67) 6 (2 to 213)
Raloxifene II [28] 48 7705 278/5129 225/2576 0.62 (0.52 to 0.73) 31 (21 to 48)
Raloxifene I [30] 36 7705 272/5129 231/2576 0.59 (0.5 to 0.7) 28 (20 to 42)
Risedronate [38] 36 1641 61/821 93/820 0.66 (0.48 to 0.89) 26 (14 to 83)
Risedronate [72] 36 816 53/408 89/408 0.6 (0.44 to 0.81) 12 (7 to 26)
Risedronate [22] 36 132 28/88 20/44 0.7 (0.44 to 1.11) 8 (3 to –42)
Clinical vertebral fractures
Alendronate [11] 48 3658 38/1841 67/1817 0.56 (0.38 to 0.82) 62 (36 to 169)
Alendronate [10] 36 2027 23/1022 50/1005 0.45 (0.28 to 0.73) 37 (22 to 84)
Raloxifene [30] 36 7705 86/5129 81/2576 0.53 (0.4 to 0.72) 69 (44 to 136)
a The number of patients to be treated to avoid one radiological vertebral fracture over the duration of the study
Table 1 Calculated relative risk (RR), number needed to treat
(NNT)a and respective 95% confidence intervals (CI) of radiologi-
cal and clinical vertebral fractures in women with postmenopausal
osteoporosis (NPFx number of patients with at least one vertebral
fracture, NPR number of patients randomized, by treatment group,
bold type indicates significant outcomes)
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200 and 400 IU/day) reported here is not significant. Ac-
cordingly, the NNT is 23, with a 95% CI of 10 to –154.
Parathormone
Two published studies were eligible [51, 61]. Vertebral
fracture risk was significantly reduced, by 68% (RR 0.32,
95%CI 0.22 to 0.46) in the endpoint trial [61], with an
NNT of 13 (95%CI 9 to 20). In the other smaller trial, the
risk reduction was not significant [51].
Raloxifene
Two publications report vertebral fracture data with raloxi-
fene at 36 months [30] and in the 12 months extension
[28]. The calculated vertebral fracture risk is significantly
reduced, by 41% after 3 years and 38% after 4 years. The
calculated NNTs are 28 (95%CI 20 to 42), and 31 (95%CI
21 to 48) respectively.
Risedronate
Risedronate significantly reduced calculated vertebral frac-
ture risk, by 34% and 40% respectively, in two endpoint
studies [38, 72]. In a third, smaller, study over 36 months,
the risk reduction was not significant (RR 0.7, 95%CI
0.44 to 1.11) [22]. Calculated NNTs ranged from 8
(95%CI 3 to –42) to 26 (95%CI 14 to 83).
Other treatment options
Calcitriol, etidronate, fluoride and pamidronate showed
calculated vertebral fracture risk reduction in single stud-
ies, while there is no publication demonstrating vertebral
fracture risk reduction over 36 months for calcium-vita-
min D, hormone replacement therapy or ipriflavone (Ta-
ble 1).
Clinical (symptomatic) vertebral fractures
Clinical vertebral fractures were defined as clinically di-
agnosed and radiologically confirmed vertebral fractures,
i.e. clinical fractures are usually symptomatic (back pain,
height loss, kyphosis). Only two drugs had published data
regarding risk reduction of symptomatic vertebral frac-
tures. According to two reports, alendronate reduced the
calculated risk for symptomatic vertebral fracture signifi-
cantly, by 44% and 55% respectively (RR 0.56; 95%CI
0.38 to 0.82 and RR 0.45; 95%CI 0.28 to 0.73 respec-
tively) [10, 11]. Raloxifene reduced the risk of clinical
fracture by 47% (RR 0.53; 95%CI 0.4 to 0.72) [30] (Table 1).
Discussion
Postmenopausal osteoporosis
In women with postmenopausal osteoporosis, vertebral frac-
tures can be prevented with efficacious drug treatments.
Oral bisphosphonates (specific inhibitors of osteoclastic
bone resorption: alendronate and risedronate), oral SERMs
(selective estrogen receptor modulators: raloxifene) and
Fig. 1 Radiological vertebral
fractures in women with post-
menopausal osteoporosis: rela-
tive risks (solid diamond) and
95% confidence intervals fol-
lowing treatment with selected
osteoporosis drugs
subcutaneous PTH (amino-terminal parathyroid hormone
1–34: teriparatide) have demonstrated their clinical effi-
cacy in large-scale trials with fractures as a primary end-
point. Calcium and vitamin D have no long-term clinical
data to demonstrate their anti-fracture efficacy in the spine;
however, calcium (500–1000 mg/day) and/or vitamin D
substitution (400–800 IU/day) were always given to all
patients in all treatment groups of all published clinical
trials. Therefore, calcium and/or vitamin D substitution
has to be considered as the established standard of all drug
interventions against osteoporosis, even in the absence of
conclusive fracture reduction endpoint data. Hormone re-
placement therapy (HRT) has not shown documented ver-
tebral fracture risk reduction in large-scale trials to date.
However, the effect of HRT on fracture risk (hip fractures
and all clinical fractures) has been extensively studied.
Hormones have systemic effects, some of which may be
expected to be beneficial, others less so. Two recently pub-
lished studies in 2,763 and 16,608 postmenopausal women
respectively have shed a new light on the antifracture effi-
cacy of HRT and its systemic effects. In the HERS trial, a
randomized, double-blind, placebo-controlled secondary
cardio-vascular prevention trial with combined estrogens
and progestin in 2,763 postmenopausal women with doc-
umented coronary heart disease, where less than 15% of
the women had osteoporosis at inclusion [19, 42, 43],
HRT had no significant effect on clinical fractures (RR
0.95, 95%CI 0.75 to 1.21) nor on hip fractures (RR 1.10;
95%CI 0.49 to 2.5) nor on breast cancer incidence, nor on
coronary heart disease, nor on stroke. Risk for venous
thrombotic disease was significantly greater with HRT
(RR 2.89; 95%CI 1.50 to 5.58) [42]. In the WHI trial, a
randomized, double-blind, placebo-controlled trial with
combined estrogens and progestin designed to assess the
major health benefits and risks of combined HRT in
16,608 postmenopausal women who had not undergone
hysterectomy, clinical and hip fracture risk was signifi-
cantly reduced, by 24 and 34% respectively. However, risk
for breast cancer, coronary heart disease, venous throm-
botic disease and stroke was significantly increased with
HRT [95]. The authors concluded that, in this trial, health
risks exceeded the benefits from use of combined estro-
gen plus progestin in healthy postmenopausal women
over a 5.2-year period of observation [95]. Therefore,
HRT should be reserved for short-term treatment of post-
menopausal symptoms and other drug alternatives consid-
ered for treatment or prevention of osteoporosis.
Osteoporosis is a systemic disease. Therefore, drugs
that have been shown to reduce the risk of fracture at all
clinically relevant sites, especially at the hip, should be-
come preferred treatment options. Based on published
data to date in postmenopausal women with osteoporosis,
alendronate significantly reduced hip fracture risk, by
51% [10, 11], risedronate by 30% [56], while calcitonin
[20], raloxifene [28, 30] and PTH [61] had no significant
effect. The calculated numbers needed to treat, i.e. the
number of patients to be treated to avoid one radiological
vertebral fracture over the duration of the study, are com-
parable with NNTs calculated in other therapeutic fields
for interventions usually considered as being good med-
ical practice. The NNT of gemfibrozil in male patients
with high cholesterol is 71 over 5 years to avoid one coro-
nary event [40], the NNT to avoid one myocardial infarc-
tion with aspirin in healthy males is 111 over 5 years [84],
and the NNT to avoid one serious gastrointestinal compli-
cation with misoprostol in rheumatoid arthritis patients is
263 over 6 months [83]. If taking additionally the fracture
risk reductions achieved at all clinical fracture sites into
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Fig. 2 Incidences of radiologi-
cal vertebral fractures in the
control group of women with
postmenopausal osteoporosis
(fractures per 1000 patient-
years)
account, the NNTs for a drug intervention in osteoporosis
would be expected to be even lower. This supposes that
patients are well diagnosed by DEXA bone mineral den-
sity measurement at the hip or the spine, showing a T-score
lower than or equal to –2.5 SD with or without anamnes-
tic fractures, before getting drug therapy. An interesting
finding was the great disparity in fracture incidences in
the control groups of the selected trials (Fig. 2). They re-
flect the differences in definitions of vertebral fractures on
the one hand and the fracture risk of the analysed patient
population on the other. The definitions of radiological
vertebral fractures used in the different trials range from a
15% reduction in vertebral height, including worsening of
pre-existing fractures, to 20% reduction in vertebral height
and more than 4 mm. Therefore, an expected finding
would be that the most stringent definition will result in
fewer fractures being detected than the looser one, inde-
pendently of the antifracture efficacy of the drug. Some
studies have included patients with low BMD (T-score be-
low –2 SD) and no fractures, while others included pa-
tients with up to five pre-existent vertebral fractures. There-
fore, an expected finding would be that the studies includ-
ing highest-risk patients would show a greater fracture in-
cidence, including in the control group. However, these
studies may fail to be representative of the patients in
which the drug will be used later in daily practice. The
calculated NNTs should therefore be interpreted in this
light, considering that in some cases less efficacious drugs
have the best NNTs.
This review has several limitations. Firstly, we excluded
from the analysis all studies of less than 36 months’ dura-
tion. However, osteoporosis is a chronic, slowly debilitat-
ing disease, and European CPMP and US American FDA
regulations require 36 months’ data for registration of an
osteoporosis drug [14]. Our results are in line with those
of an exhaustive meta-analysis [65] and a recent review
[39], which reached similar conclusions. Secondly, we ex-
cluded all studies reporting fracture rates only, and con-
sidered only studies reporting patients with at least one
vertebral fracture. However, the drawback of the loss of
data of isolated studies was outweighed by far by the im-
proved quality of the remaining data, especially as the
present review focused on vertebral fractures. In fact, for
statistical analysis, the basic assumption is that all events
can be regarded as independent; a second event in the same
patient being as likely as a first event in this or in another
patient. Vertebral fractures are not independent events [93].
By considering only patients with fractures (i.e., the true
fracture incidence and not the fracture rate), the informa-
tion about the drug effect on the risk reduction of multiple
fractures is lost, and separate analyses would be required
to answer this question. One publication addresses the
risk reduction for multiple symptomatic fractures with
alendronate, showing a significant risk reduction, of 84%
(RR 0.16; 95%CI 0.05 to 0.42) [49].
Osteoporosis in men
Osteoporosis in men is more often secondary than pri-
mary. Therefore, the underlying cause (drug-induced bone
loss, gastro-intestinal diseases, hypercalciuria, endocrine
disorders, etc) must be identified and treated first. The best
documented drug intervention is with alendronate, which
showed similar efficacy in men and in postmenopausal
women with regard to achieved increases in BMD. The
studies were not statistically powered to evaluate the effi-
cacy on vertebral fracture risk reduction; however, both
showed a trend in favor of alendronate [64, 78]. Pooled
results of two studies with risedronate in 184 men receiv-
ing chronic steroid therapy showed a significant reduction
in the risk of vertebral fracture over 1 year of treatment
[75]. As is the case in women, calcium and vitamin D de-
ficiency have been prevented by systematic calcium sub-
stitution.
Glucocorticosteroid-induced osteoporosis
Glucocorticosteroid-induced osteoporosis (GIO) is by far
the most frequent cause of secondary osteoporosis [4, 89],
and fracture incidence under corticosteroids may be as
high as 50% [3]. The pathogenesis of GIO is complex:
proposed mechanisms include decreased osteoblast prolif-
eration and biosynthetic activity as well as increased bone
resorption [18], sex-steroid deficiency, decreased intesti-
nal calcium absorption and secondary hyperparathyroid-
ism [47]. Fracture risk is dose dependent, rises within the
first months under glucocorticoid treatment, and remains
elevated over the entire duration of therapy [87]. How-
ever, even short courses of oral corticosteroids or inhaled
corticosteroids may be deleterious to bone [87, 94].
The comparative efficacy with respect to bone mineral
density of several therapeutic agents for the management
of GIO has been recently determined using meta-regres-
sion models [8]. Bisphosphonates were the most effective
of the evaluated agents, whereas calcitonin and vitamin D
were more effective than no therapy or calcium. Promis-
ing data with respect to BMD have furthermore been ob-
tained with PTH, which had not yet been included in that
meta-analysis of 2002 [48]. However, for all mentioned
therapeutic strategies in GIO, fracture data are scarce, since
many of the trials had a preventive design and were of
short duration (1 or 2 years), including only modest num-
bers of patients with small numbers of fractures [1, 2, 23,
25, 74, 75, 81, 82, 88].
Using cyclical etidronate in 141 men and women who
had recently begun high-dose corticosteroid therapy, Adachi
et al. found no significant reduction in vertebral fracture
incidence compared with the placebo group overall after
12 months [1]. However, among postmenopausal women
1/31 in the etidronate group versus 7/32 women receiving
placebo experienced new vertebral fractures, demonstrat-
S137
S138
ing an anti-fracture effect of marginal significance (P=
0.05). The combined results of two parallel 12-months tri-
als (one conducted in the US, one in 15 other countries)
using alendronate in a total of 477 men and women who
had been under glucocorticoid therapy for a varying dura-
tion (34% for less than 4 months, 21% for 4–12 months,
45% for more than 12 months) were quite similar com-
pared with those of the etidronate trial. Again they showed
no significant difference in overall incidence between the
bisphosphonate and placebo groups (P=0.18), but there
was a borderline significance, of P=0.05, in postmeno-
pausal women, when a post-hoc binary semiquantitative
fracture assessment was used (7/54 patients with new ver-
tebral fractures in the placebo versus 6/135 in the alen-
dronate group) [81]. Although patients had a relatively low
background prevalence of vertebral fractures (12–15%)
the reduction in the incidence of vertebral fractures under
alendronate became significant in a sample of patients
(144 women, 66 men) in which that combined trial was
extended to 24 months (overall 4/59 patients of the
placebo group and 1/143 patients in the alendronate group
experienced new morphometric fractures over 2 years,
P=0.026) [2]. A recent comparative 2-years trial between
calcitriol, vitamin D plus calcium and alendronate plus
calcium in 195 subjects (134 women, 61 men) commenc-
ing or already taking glucocorticoids showed that alen-
dronate was superior to the other two treatment regimens
for glucocorticoid-induced bone loss, especially in the
spine [82]. Six of 66 subjects treated with calcitriol, 1 of
61 treated with ergocalciferol, and 0 of 64 treated with al-
endronate sustained new vertebral fractures. That study was
not powered for a fracture endpoint; however, it is inter-
esting to note that, as in all the above-mentioned studies,
no vertebral fractures occurred in premenopausal women.
The efficacy of risedronate was evaluated in two 1-year
studies for prevention [23] and treatment [74]. The pre-
vention trial included 224 men and women who had be-
gun to take glucocorticoids within the previous 3 months.
The treatment study included 285 men and women who
had been under glucocorticoids for at least 6 months.
Risedronate reduced the risk of new vertebral fractures by
71% (P=0.072) in the prevention trial and by 70% (P=
0.042) in the treatment trial. When data from these two
studies were combined, risedronate led to a 70% (P=0.01)
reduction in the risk of vertebral fracture relative to placebo
[88]: after 1 year, 18/111 patients (16%) under placebo
and 12/195 patients (6%) under risedronate experienced
new morphometric vertebral fractures. The significant an-
tifracture effect in that combined study was reached for all
patients together and for postmenopausal women, only. 
A separate (post hoc) analysis of male data from these two
parallel risedronate trials on an intent to treat basis re-
vealed a significant antifracture efficacy also for men un-
der glucocorticoid treatment (P=0.008) [75].
Although more effective than calcium alone in main-
taining lumbar BMD [8], calcitonin failed to reduce frac-
ture risk in the spine or femoral neck in GIO [25].
The antifracture efficacy of PTH in that special condi-
tion remains to be proven.
Management of acute and chronic pain
Most osteoporotic vertebral fractures are asymptomatic.
In the clinical trials that analyzed radiological and clinical
vertebral fractures, symptomatic fractures represented 35%
of all radiological fractures [10, 11, 30]. However, even
asymptomatic fractures lead to spine deformity with chronic
back pain and progressive disability. The management of
chronic back pain relies on analgesics (paracetamol), non
steroidal anti-inflammatory drugs (NSAIDs), and, more
recently, on selective COX-II inhibitors (coxibs), which
have demonstrated equal efficacy in pain relief and an im-
proved gastrointestinal safety profile as compared to
NSAIDs [13, 57]. Calcitonin, administered subcutaneously
or intranasally, has demonstrated excellent analgesic effi-
cacy in some patients [12]. Additional non-pharmacologic
interventions include physiotherapy, physical activity and
fall prevention programs.
Conclusion
The selection of the appropriate drug for treatment of ver-
tebral osteoporosis among a bisphosphonate (alendronate
or risedronate), PTH, calcitonin or raloxifene will mainly
depend on its efficacy, tolerability and safety profile to-
gether with the patient’s willingness to comply with a long-
term treatment. Although reduction of vertebral fracture
risk is an important criterion for decision-making, drugs
with proven additional fracture risk reduction at all clini-
cally relevant sites (especially at the hip) should be the
preferred options.
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